Patients being prescribed weight-loss drugs should be required to see a dietitian, the nutrition industry says as ...

The Taoiseach Micheal Martin’s White House encounter with Donald Trump was controversial even before it was announced. Before any invitation had been extended, Sinn Fein said they were going ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

After 2 positive trials, low-dose colchicine’ got the FDA nod for CV reduction but then the CLEAR SYNERGY trial found no ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.